Feature Galectin targets silent epidemic in liver fibrosis By Len Zehr Fatty liver disease, or the accumulation of fat in liver cells, is a “silent epidemic,” says Dr. Peter Traber, president, CEO and chief medical officer of Galectin Therapeutics (NASDAQ:GALT). In an interview... August 20, 2013